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Abstract 16 
The reaction of [(p-cymene)RuCl2]2  and [Cp*MCl2]2 (M = Rh/Ir) with benzoyl(2-17 
pyrimidyl)thiourea (L1) and benzoyl(4-picolyl)thiourea (L2) led to the formation of cationic 18 
complexes bearing formula [(arene)M(L1)к2(N,S)Cl]+ and [(arene)M(L2)к2(N,S)Cl]+ [(arene) = p-19 
cymene, M = Ru, (1, 4); Cp*, M = Rh (2, 5) and Ir (3, 6)]. Precursor compounds reacted with 20 
benzoyl(6-picolyl)thiourea (L3) affording neutral complexes having formula 21 
[(arene)M(L3)к1(S)Cl2] [arene = p-cymene, M = Ru, (7); Cp*, M = Rh (8), Ir (9)]. X-ray studies 22 
revealed that the methyl substituent attached to the pyridine ring in ligands L2 and L3 affects its 23 
coordination mode. When methyl group is at the para position of the pyridine ring (L2), the 24 
ligand coordinated metal in a bidentate chelating N, S- mode whereas methyl group at ortho 25 
position (L3), it coordinated in a monodentate mode. Further the anti-cancer studies of the 26 
thiourea derivatives and its complexes carried out against HCT-116, HT-29 (human colorectal 27 
cancer), Mia-PaCa-2 (human pancreatic cancer) and ARPE-19 (non-cancer retinal epithelium) 28 
cell lines showed that the thiourea ligands are inactive but upon complexation, the metal 29 
compounds displayed potent and selective activity against cancer cells in vitro. Iridium 30 
complexes were found to be more potent as compared to ruthenium and rhodium complexes. 31 
Keywords: Ruthenium, rhodium, iridium, thiourea, cytotoxicity  32 
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Introduction 33 
Ruthenium based organometallic complexes have evolved as a promising candidates as 34 
anti-cancer agents having potential clinical applications in particularly against cisplatin resistant 35 
tumors.[1] Half-sandwich arene ruthenium(II) complexes are currently the subject of versatile 36 
research which have the capability to act as metal-based anti-cancer drugs.[2,3] In particularly two 37 
such complexes developed by Sadler’s group [Ru(η6-arene)Cl(en)]+ (en = ethylenediamine) and 38 
Dyson’s group [Ru(η6-toluene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphaadamantane) have been 39 
extensively studied and found to have excellent anti-tumor properties.[4-6] The organometallic 40 
scaffold present in the ruthenium arene complexes presents an ideal platform for the design of 41 
these half-sandwich complexes. The basic building blocks in these complexes include the arene 42 
ligand which controls the hydrophobicity and interactions with biomolecules, labile chloride 43 
ligand which enables coordination of the metal with protein and nucleic acids.[7,8] Rhodium and 44 
iridium pentamethylcyclopentadienyl complexes have also been studied by various research 45 
groups for their anti-proliferative activities.[9,10] These complexes have also displayed their 46 
remarkable activity as catalyst for various organic transformation reactions.[11-13] 47 
Much interest has been paid towards the coordination chemistry of benzoylthiourea 48 
ligands because of their interesting and versatile coordination behavior towards various transition 49 
metals. These ligands possesses various hetero donor atoms which can coordinate metal in 50 
several coordination modes such as monobasic bidentate (O, S), neutral monodentate (S), and 51 
neutral bidentate (O, N) coordination modes.[14,15] Rhodium complex of N-benzoyl-N´-52 
phenylthiourea ligand has been reported wherein the ligand acted as bridging ligand coordinating 53 
one rhodium center in a bidentate fashion through (O, S) mode and the other through 54 
deprotonated nitrogen.[16] Substitution of alkyl or aryl group with various other substituents is 55 
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expected to alter the coordination modes of these ligands. When the alkyl or aryl group is 56 
replaced by a pyridyl group the ligand acted as neutral bidentate ligand coordinating metal in a 57 
(N, S) mode.[17,18] Transition metal complexes of various thiourea derived ligands have been 58 
evaluated for their anti-bacterial, anti-cancer and anti-microbial activities.[19-21] In our present 59 
work we report the synthesis spectral and molecular structures of ruthenium, rhodium and 60 
iridium half-sandwich complexes containing pyridyl and pyrimidyl thiourea derivatives. Ligands 61 
used in the present study are shown in Chart 1. 62 
Experimental 63 
Materials and Methods 64 
The reagents used were of commercial quality and used without further purification. 65 
Metal salts RuCl3.nH2O, RhCl3.nH2O and IrCl3.nH2O were purchased from Arora Matthey 66 
Limited. α-phellandrene, pentamethylcyclopentadiene, 2-amino pyrimidine, 2-amino-4-methyl 67 
pyridine and 2-amino-6-methyl pyridine were purchased from Sigma-Aldrich and 68 
benoylisothiocyanate was purchased from Alfa-Aesar. The solvents were dried and distilled prior 69 
to use according to standard procedures.[22] The thiourea derivatives (L1-L3) were prepared 70 
according to published procedures.[23,24] Precursor metal complexes [(p-cymene)RuCl2]2 and 71 
[Cp*MCl2]2 (M = Rh/Ir) were prepared according to the published procedures.
[25,26] 1H NMR 72 
spectra were recorded on a Bruker Avance II 400 MHz spectrometer using CDCl3 as solvent; 73 
chemical shifts were referenced to TMS. Infrared spectra (KBr pellets; 400-4000 cm-1) were 74 
recorded on a Perkin-Elmer 983 spectrophotometer. Mass spectra were recorded in positive 75 
mode with Q-Tof APCI-MS instrument (model HAB 273) using acetonitrile as solvent. 76 
Elemental analyses of the complexes were carried out on a Perkin-Elmer 2400 CHN/S analyzer. 77 
 78 
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Structure determination by X-ray crystallography 79 
Solvent diffusion method was used for growing single crystals of compounds. Suitable 80 
single crystals for X-ray structure analysis have been obtained for [2]PF6 and [3]PF6, available 81 
from [2]Cl and [3]Cl and (4, 5, 6, 7, 8 and 9) in a dichloromethane-hexane mixture. The PF6 salts 82 
for complexes (2 and 3) were obtained by dissolving quantitative amount of chloride salts i.e. 83 
[2]Cl and [3]Cl in acetonitrile and adding excess amounts of ammonium hexafluorophosphate 84 
whereupon ammonium chloride precipitated out immediately. This solution was then filtered 85 
over celite and the solvent was evaporated under reduced pressure to afford yellow solid which 86 
was washed with diethyl ether (2x 5 mL) and air dried. This compound was utilized for growing 87 
single crystals for complexes (2 and 3). Single crystal data for the complexes were collected with 88 
an Oxford Diffraction Xcalibur Eos Gemini diffractometer using graphite monochromated Mo-89 
Kα radiation (λ = 0.71073 Å). The strategy for the data collection was evaluated using the 90 
CrysAlisPro CCD software. Crystal data were collected by standard ‘‘phi–omega scan’’ 91 
techniques and were scaled and reduced using CrysAlisPro RED software. The structures were 92 
solved by direct methods using SHELXS-97 and refined by full-matrix least squares with 93 
SHELXL-97 refining on F2.[27,28]. The positions of all the atoms were obtained by direct 94 
methods. Metal atoms in the complex were located from the E-maps and all non-hydrogen atoms 95 
were refined anisotropically by full-matrix least-squares. Hydrogen atoms were placed in 96 
geometrically idealised positions and constrained to ride on their parent atoms with C-H 97 
distances in the range 0.95-1.00 Angstrom. Isotropic thermal parameters Ueq were fixed such that 98 
they were 1.2Ueq of their parent atom Ueq for CH's and 1.5Ueq of their parent atom Ueq in case of 99 
methyl groups. Crystallographic and structure refinement parameters for the complexes are 100 
summarized in (Table S1 & S2) and selected bond lengths and bond angles are presented in 101 
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(Table S3). Figures 1-3 were drawn with ORTEP3 program whereas Figures 4-6 was drawn 102 
using MERCURY 3.6 program.[29] 103 
The crystal structure of complex (4) contains disordered CHCl3 and H2O molecule. The 104 
asymmetric unit in complex (5) contains two molecules along with a H2O molecule. Crystal 105 
structure of complex (6) contains H2O molecule in its solved structure. Asymmetric unit in 106 
complex (7) contains two molecules. 107 
Cell lines testing, culture conditions and cytotoxicity against cell lines 108 
The in vitro cytotoxicity of the thiourea derivatives (L1-L3) and its corresponding arene 109 
d6 metal complexes were performed at the University of Huddersfield against Mia-PaCa-2 110 
human pancreatic cancer cell line, HT-29 and HCT-116 human colorectal carcinoma cell lines 111 
and the non-cancer ARPE-19 human epithelial cell line. The cell lines were originally purchased 112 
from ATCC and the reagents used were purchased from Sigma Aldrich Co. Ltd (Dorset, UK) 113 
unless otherwise stated. Antiproliferative activity of the compounds was evaluated using the 114 
standard MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cellular viability 115 
assay as described elsewhere.[30] Briefly cells were seeded into 96 well plates at 1.5 x 103 cells 116 
per well and incubated for 24 hours at 37°C in an atmosphere of 5% CO2 prior to drug exposure. 117 
Generally, a stock solution was freshly prepared by dissolving each of the compounds in 118 
dimethylsulphoxide at a concentration of 100 mM which was subsequently diluted with medium 119 
to obtain drug solutions ranging from 0.5 to 100 μM. The final dimethylsulphoxide concentration 120 
was 0.1% (v/v), which is nontoxic to cells. Cisplatin was dissolved in phosphate buffered saline 121 
at a stock concentration of 25 mM. The cells were exposed to a range of drug concentrations for 122 
96 hours and cell survival was determined using the MTT assay.[29,30] Following drug exposure 123 
20 µL of MTT (0.5 mg/ mL) in phosphate buffered saline was added to each well and it was 124 
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further incubated at 37 °C for 4 hours in an atmosphere containing 5% CO2. The solution was 125 
then removed and the formed formazan crystals were dissolved in 150 µM dimethylsulphoxide. 126 
The absorbance of the resulting solution was recorded at 550 nm using an ELISA 127 
spectrophotometer. The percentage of cell survival was calculated by dividing the true 128 
absorbance of treated cell by the true absorbance for controls (exposed to 0.1% 129 
dimethylsulphoxide). The IC50 values were determined from plots of % survival against drug 130 
concentration. Each experiment was performed in triplicate and a mean value obtained and stated 131 
as IC50 (µM) ± SD. To compare the response of non-cancer cells to cancer cells, the selectivity 132 
index (SI) was also calculated which is defined as the IC50 for ARPE-19 cells divided by the IC50 133 
for each cancer cell line. Values >1 indicate that complexes have selective activity against cancer 134 
compared to non-cancer cells in vitro. 135 
General procedure for preparation of thiourea metal complexes (1-9) 136 
A mixture of metal precursor [(p-cymene)RuCl2]2 or [Cp*MCl2]2 (M = Rh/Ir) (0.1 mmol) 137 
and thiourea derivatives (L1-L3) (0.2 mmol) were dissolved in dry acetone (10 mL) and stirred at 138 
room temperature for 8 hours (Scheme 1). A yellow colored compound precipitated out from the 139 
reaction mixture. The precipitate was filtered, washed with cold acetone (2 x 5 mL) and diethyl 140 
ether (3 x 10 mL) and air dried. 141 
[(p-cymene)Ru(L1)к2(N,S)Cl]Cl (1) 142 
Yield 90 mg (79%); Anal. Calc. for C22H24Cl2N4OSRu (564.49): C, 46.81; H, 4.29; N, 9.93. 143 
Found: C, 46.93; H, 4.38; N, 9.88 %; FT-IR (KBr, cm-1): 3430(b), 3045(w), 1710(s), 1585(m), 144 
1559(m), 1257(m), 1175(m); 1H NMR (400 MHz, CDCl3): δ = 14.33 (s, 1H, NH), 9.13 (d, J = 4 145 
Hz, 1H), 8.76 (s, 1H, NH), 8.59 (d, J = 4 Hz, 1H), 8.39 (d, J = 8 Hz, 2H), 7.44-7.59 (m, 4H), 146 
5.47 (d, J = 4 Hz, 2H, CH(p-cym)), 5.31 (d, J = 8 Hz, 2H, CH(p-cym)), 2.85 (sept, 1H, CH(p-cym)), 2.11 147 
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(s, 3H, CH(p-cym)), 1.27 (d, J = 8 and 8 Hz, 6H, CH(p-cym)); 13C NMR (100 MHz, CDCl3): δ = 148 
180.05, 166.20, 160.67, 156.28, 134.06, 131.14, 129.46, 128.96, 119.05, (C-L1), 107.33, 101.48, 149 
88.35, 86.63, 85.99, 85.46, 30.72, 22.32, 18.35 (C-p-cym); HRMS-APCI (m/z) [Found (Calcd)]: 150 
[492.0578 (492.0558)] [M-2H-2Cl+H]+. 151 
[Cp*Rh(L1)к2(N,S)Cl]Cl (2) 152 
Yield 87 mg (76%); Anal. Calc. for C22H25Cl2N4OSRh (556.01): C, 46.57; H, 4.44; N, 9.88. 153 
Found: C, 46.68; H, 4.56; N, 9.95 %; FT-IR (KBr, cm-1): 3424(b), 3076(w), 1712(s), 1599(m), 154 
1580(w), 1257(m), 1177(m); 1H NMR (400 MHz, CDCl3): δ = 14.42 (s, 1H, NH), 9.02 (dd, J = 155 
4 and 4 Hz, 1H), 8.81 (s, 1H, NH), 8.62 (d, J = 4 Hz, 1H), 8.38 (d, J = 8 Hz, 2H), 7.51-7.63 (m, 156 
4H), 1.64 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, CDCl3): δ = 178.63, 161.42, 161.13, 133.78, 157 
129.48, 128.83, 127.68, 119.58 (C-L1), 96.13 (Cp*ipso), 8.89 (Cp*Me); HRMS-APCI (m/z) 158 
[Found (Calcd)]: [494.0672 (494.0648)] [M-2H-2Cl+H]+. 159 
[Cp*Ir(L1)к2(N,S)Cl]Cl (3) 160 
Yield 93 mg (70%); Anal. Calc. for C22H25Cl2N4OSRh (656.64): C, 40.24; H, 3.84; N, 8.53. 161 
Found: C, 40.32; H, 3.93; N, 8.64 %, FT-IR (KBr, cm-1): 3431(b), 3120(m), 1714(s), 1596(m), 162 
1588(w), 1258(m), 1176(m); 1H NMR (400 MHz, CDCl3): δ = 14.31 (s, 1H, NH), 8.91 (dd, J = 163 
4 and 4 Hz, 1H), 8.75 (s, 1H, NH), 8.61 (d, J = 4 Hz, 1H), 8.37 (d, J = 4 Hz, 1H), 7.60 (t, J = 8 164 
Hz, 2H), 7.52 (t, J = 8 Hz, 2H), 7.23 (m, 1H), 1.84 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, 165 
CDCl3): δ = 178.31, 162.13, 161.22, 155.25, 134.02, 131.24, 129.46, 128.94, 119.88, 111.67, (C-166 
L1), 90.80 (Cp*ipso), 8.62 (Cp*Me); HRMS-APCI (m/z) [Found (Calcd)]: [584.1256 (584.1222)] 167 
[M-2H-2Cl+H]+. 168 
[(p-cymene)Ru(L2)к2(N,S)Cl]Cl (4) 169 
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Yield 98 mg (85%); Anal. Calc. for C24H27Cl2N3OSRh (577.02): C, 49.91; H, 4.71; N, 7.28. 170 
Found: C, 50.02; H, 4.87; N, 7.37 %; FT-IR (KBr, cm-1): 3434(b), 3064(w), 1707(m), 1606(m), 171 
1571(m), 1482(m), 1241(m) 1222(m); 1H NMR (400 MHz, CDCl3): δ = 14.14 (s, 1H, NH), 172 
12.84 (s, 1H, NH), 8.77 (d, J = 4 Hz, 1H), 8.41 (d, J = 8 Hz, 2H), 7.56-7.67 (m, 4H), 7.11 (d, J = 173 
8 Hz, 1H), 5.67 (d, J = 4 Hz, 1H, CH(p-cym)), 5.59 (d, J = 4 Hz, 1H, CH(p-cym)), 5.40 (d, J = 4 Hz, 174 
2H, CH(p-cym)), 2.93 (sept, 1H, CH(p-cym)), 2.48 (s, 3H, CH3(py)), 2.00 (s, 3H, CH(p-cym)), 1.30 (d, J 175 
= 8 and 8 Hz, 6H, CH(p-cym)); 13C NMR (100 MHz, CDCl3): δ = 178.66, 164.70, 153.53, 152.26, 176 
149.89, 132.89, 130.38, 128.01, 122.81, 116.59, 21.42 (C-L2), 105.75, 99.93, 86.97, 85.26, 177 
84.90, 83.54, 29.69, 20.02, 17.29 (C-p-cym); HRMS-APCI (m/z) [Found (Calcd)]: [507.0883 178 
(507.0852)] [M-2H-2Cl+H]+. 179 
[Cp*Rh(L2)к2(N,S)Cl]Cl (5) 180 
Yield 103 mg (88%); Anal. Calc. for C24H28Cl2N3OSRh (580.35): C, 49.67; H, 4.86; N, 7.24. 181 
Found: C, 49.76; H, 4.83; N, 7.38 %; FT-IR (KBr, cm-1): 3440(b), 3067(w), 1709(m), 1607(m), 182 
1583(m), 1489(m), 1245(m) 1228(m); 1H NMR (400 MHz, CDCl3): δ = 14.09 (s, 1H, NH), 183 
12.72 (s, 1H, NH), 8.49 (d, J = 4 Hz, 1H), 8.31 (d, J = 8 Hz, 2H), 7.61 (s, 1H, CH(py)), 7.47-7.56 184 
(m, 4H), 7.08 (d, J = 4 Hz, 1H), 2.39 (s, 3H, CH3(py)), 1.54 (s, 15H, CH(Cp*)); 13C NMR (100 185 
MHz, CDCl3): δ = 178.32, 165.68, 153.61, 151.94, 150.0, 139.91, 131.47, 129.07, 129.00, 186 
124.84, 118.19, 21.12 (C-L2), 97.50 (Cp*ipso), 8.85 (Cp*Me); HRMS-APCI (m/z) [Found 187 
(Calcd)]: [508.0924 (508.0934)] [M-2H-2Cl+H]+. 188 
[Cp*Ir(L2)к2(N,S)Cl]Cl (6) 189 
Yield 103 mg (77%); Anal. Calc. for C24H28Cl2N3OSIr (669.68): C, 43.04; H, 4.21; N, 6.27. 190 
Found: C, 43.13; H, 4.28; N, 6.41 %; FT-IR (KBr, cm-1): 3441(b), 3083(w), 1703(m), 1606(m), 191 
1586(m), 1475(m), 1243(m) 1217(m); 1H NMR (400 MHz, CDCl3): δ = 13.95 (s, 1H, NH), 192 
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12.79 (s, 1H, NH), 8.49 (d, J = 8 Hz, 1H), 8.40 (d, J = 8 Hz, 2H), 7.74 (s, 1H, CH(py)), 7.64 (t, J = 193 
8 Hz, 1H), 7.57 (t, J = 8 Hz, 2H), 7.07 (d, J = 4 Hz, 1H), 2.50 (s, 3H, CH3(py)), 1.61 (s, 15H, 194 
CH(Cp*)); 13C NMR (100 MHz, CDCl3): δ = 177.72, 164.18, 153.70, 152.89, 151.02, 138.41, 195 
133.82, 129.06, 128.97, 124.72, 117.87, 21.03 (C-L2), 90.05 (Cp*ipso), 8.54 (Cp*Me); HRMS-196 
APCI (m/z) [Found (Calcd)]: [598.1529 (598.1504)] [M-2H-2Cl+H]+. 197 
[(p-cymene)Ru(L3)к1(S)Cl2] (7) 198 
Yield 103 mg (89%); Anal. Calc. for C24H27Cl2N3OSRh (577.02): C, 49.91; H, 4.71; N, 7.28. 199 
Found: C, 50.02; H, 4.87; N, 7.37 %; FT-IR (KBr, cm-1): 3447(b), 3038(w), 1715(m), 1620(m), 200 
1552(m), 1446(m), 1384(m), 1250(m); 1H NMR (400 MHz, CDCl3): δ = 15.36 (s, 1H, NH), 201 
10.92 (s, 1H, NH), 8.07 (d, J = 8 Hz, 2H), 7.60-7.66 (m, 2H), 7.54 (t, J = 8 Hz, 2H), 7.03 (d, J = 202 
8 Hz, 1H), 6.95 (d, J = 8 Hz, 1H), 5.54 (d, J = 8 Hz, 2H, CH(p-cym)), 5.37 (d, J = 8 Hz, 2H, CH(p-203 
cym)), 3.12 (sept, 1H, CH(p-cym)), 2.48 (s, 3H, CH3(py)), 2.33 (s, 3H, CH(p-cym)), 1.36 (d, J = 4 Hz, 204 
6H, CH(p-cym)); 13C NMR (100 MHz, CDCl3): δ = 175.86, 164.59, 154.33, 151.08, 139.32, 205 
132.94, 132.86, 128.39, 127.75, 119.8, 112.35, 21.76 (C-L3), 103.51, 99.61, 84.02, 82.98, 29.88, 206 
23.26, 17.89 (C-p-cym); HRMS-APCI (m/z) [Found (Calcd)]: [505.0734 (505.0762)] [M-2H-207 
2Cl+H]+. 208 
[Cp*Rh(L3)к1(S)Cl2] (8) 209 
Yield 92 mg (79%); Anal. Calc. for C24H28Cl2N3OSRh (580.35): C, 49.67; H, 4.86; N, 7.24. 210 
Found: C, 49.76; H, 4.83; N, 7.38 %; FT-IR (KBr, cm-1): 3443(b), 3031(w), 1715(m), 1623(m), 211 
1554(m), 1452(m), 1394(m), 1253(m); 1H NMR (400 MHz, CDCl3): δ = 15.47 (s, 1H, NH), 212 
11.14 (s, 1H, NH), 8.08 (d, J = 8 Hz, 1H), 7.61-7.66 (m, 2H), 7.54 (t, J = 8 Hz, 2H), 7.20 (d, J = 213 
12 Hz, 1H), 6.96 (d, J = 8 Hz, 1H), 2.49 (s, 3H, CH3(py)), 1.74 (s, 15H, CH(Cp*)); 13C NMR (100 214 
MHz, CDCl3): δ = 175.24, 165.16, 153.14, 151.63, 142.88, 139.25, 133.36, 129.12, 128.02, 215 
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126.23, 119.92, 115.18, 23.43 (C-L3), 88.54 (Cp*ipso), 8.41 (Cp*Me); HRMS-APCI (m/z) 216 
[Found (Calcd)]: [542.0646 (542.0540)] [M-2H-Cl]+, [506.0881 (507.0852)] [M-2H-2Cl-1]+. 217 
[Cp*Ir(L3)к1(S)Cl2] (9) 218 
Yield 97 mg (73%); Anal. Calc. for C24H28Cl2N3OSIr (669.68): C, 43.04; H, 4.21; N, 6.27. 219 
Found: C, 43.13; H, 4.28; N, 6.41 %; FT-IR (KBr, cm-1): 3436(b), 3038(w), 1704(m), 1620(m), 220 
1550(m), 1446(m), 1384(m), 1248(m); 1H NMR (400 MHz, CDCl3): δ = 15.40 (s, 1H, NH), 221 
11.45 (s, 1H, NH), 8.0 (d, J = 8 Hz, 2H), 7.57 (t, J = 8 Hz, 2H), 7.46 (t, J = 8 Hz, 2H), 7.12 (d, J 222 
= 8 Hz, 1H), 6.91 (d, J = 8 Hz, 1H), 2.42 (s, 3H, CH3(py)), 1.63 (s, 15H, CH(Cp*)); 13C NMR (100 223 
MHz, CDCl3): δ = 175.33, 165.11, 154.91, 151.77, 139.88, 133.50, 133.36, 128.92, 128.20, 224 
127.78, 119.92, 113.34. 23.83 (C-L3), 88.98 (Cp*ipso), 8.42 (Cp*Me); HRMS-APCI (m/z) 225 
[Found (Calcd)]: [598.1507 (598.1504)] [M-2H-2Cl+H]+. 226 
Results and discussion 227 
Synthesis of complexes 228 
The work presented herein describes the synthesis of arene metal complexes containing 229 
benzoyl thiourea derivatives. The complexes (1-9) were synthesized by the reaction between 230 
precursor complexes and thiourea derivatives (L1-L3) in acetone. Scheme 1 depicts the synthesis 231 
of the metal complexes. Reaction of ligands (L1 and L2) with precursors afforded ionic 232 
complexes (1-6) which were isolated as chloride counter ion whereas reaction of (L3) afforded 233 
neutral complexes (7-9). Further X-ray analysis of these complexes revealed that the methyl 234 
substituent present at the pyridine ring in ligands (L2 and L3) affects its coordination behavior 235 
towards metal ion. Depending on the position of the methyl group attached to the pyridine ring 236 
the complexes can be isolated as neutral or ionic. In the present case when methyl group is at the 237 
para position of the pyridine ring such as in (L2) it acted as bidentate chelating ligand yielding 238 
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ionic complexes, whereas methyl group at the ortho position of the pyridine ring as in (L3) 239 
yielded neutral complexes with monodentate coordination of the ligand. All these complexes 240 
were isolated as light to dark yellow solids in moderate yields and characterized by spectroscopic 241 
and analytical techniques. Complexes (1 and 4) are not very stable in solid state and turned oily 242 
liquid which enabled us to evaluate its cytotoxicity analysis. They are soluble in common 243 
organic solvents like acetonitrile, dichloromethane, chloroform, methanol and 244 
dimethylsulphoxide but insoluble in petroleum ether, hexane and diethyl ether. Single crystal X-245 
ray diffraction analysis confirmed the different coordinating modes of the thiourea derivatives 246 
observed in this work i.e. a bidentate chelating N, S- mode and a monodentate S- mode. Further 247 
the anti-cancer activity of the ligands and its metal complexes were evaluated against cancer cell 248 
line and non-cancer cell line. 249 
Spectral studies of the complexes 250 
IR studies of metal complexes 251 
The IR spectra of the metal complexes showed stretching frequencies in the region 252 
around 3035-3450, 1770-1720, 1580-1625, and 1240-1260 cm-1 corresponding to ν(N-H), 253 
ν(C=O), ν(C=N) and ν(C=S). The N-H and C=O stretching frequencies did not show any change 254 
upon coordination of the ligands and were almost unaltered which indicates it is not involved in 255 
bonding to the metal atom. Whereas the C=S stretching frequencies appeared in the lower 256 
frequency region around 1240-1260 cm-1 as compared to the free ligand which strongly suggest 257 
the coordination of the sulfur atom of the thiocarbonyl group. In cationic complexes (1-6) the 258 
C=N stretching frequency decreases slightly as compared to free ligand and was observed in the 259 
region around 1585-1610 cm-1 which indicates involvement of pyridyl/pyrimidyl nitrogen in 260 
coordination. In contrast the C=N stretching frequencies in neutral complexes (7-9) remains 261 
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unaltered and was observed in the region around 1620-1623 cm-1. The difference in C=N 262 
stretching frequencies in neutral and cationic complexes is an indication of coordination of 263 
pyridyl/pyrimidyl nitrogen. 264 
1H NMR studies of metal complexes 265 
The 1H NMR spectra of the metal complexes confirms the coordination of the ligands to 266 
the metal center. The pyridyl and thiocarbonyl attached N-H and carbonyl and thiocarbonyl 267 
attached N-H proton signals were observed as a singlet around 10.92-15.36 ppm. For complexes 268 
(4, 5 and 6) the N-H proton resonance was observed around 8.75-8.81 ppm. The appearance of 269 
the N-H proton signals indicates that it is not involved in coordination and also suggests the 270 
neutral chelating mode of the ligands. The signals due to the aromatic protons of the ligands 271 
appeared in the downfield region around 6.44-9.13 ppm following coordination to the metal 272 
atom. In complexes (4-9), the methyl proton of the pyridine ring was observed as a singlet 273 
around 2.39-2.50 ppm respectively. The appearance of the p-cymene and Cp* ring proton signals 274 
in addition to the protons of the ligand confirms the binding of the ligand to the metal atom. The 275 
methyl proton signal of the p-cymene ligand was observed as a singlet around 2.00-2.33 ppm. 276 
The methyl protons of isopropyl group was observed as closely spaced doublet for complexes (1 277 
and 4) whereas for complex (7) it was observed as doublet around 1.27-1.36 ppm and the 278 
methine protons of the isopropyl group was observed as a septet around 2.85-3.12 ppm. The 279 
aromatic protons of p-cymene moiety displayed two doublets for complexes (1 and 7) whereas 280 
three doublets for complex (4). The methyl protons of the pentamethylcyclopentadienyl (Cp*) 281 
ligand displayed a sharp singlet around 1.54-1.84 ppm. Overall the 1H NMR spectra of the 282 
complexes exhibited the expected resonances and integration which is consistent with the 283 
formulation of the compounds. 284 
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13C{1H} NMR studies of metal complexes 285 
The 13C NMR spectra of the complexes further justify the coordination of the ligand. The 286 
13C NMR spectra of the complexes displayed signals associated with the ligand carbons, p-287 
cymene moiety carbons, methyl carbon of Cp* and ring carbon of Cp*. The 13C NMR spectra of 288 
the complexes showed signal in the range 111.6-153.4 ppm for the aromatic carbons of the 289 
thiourea derivatives. The carbon resonance of the thiocarbonyl (C=S) group appeared in the 290 
lower frequency region around 175.2-180.0 ppm whereas the carbon peak for carbonyl (C=O) 291 
group appeared in the region around 161.4-166.2 ppm. In complexes (4-9), the methyl carbon 292 
resonances of the pyridine ring were observed around 21.0-23.8 ppm. The methyl, methine and 293 
isopropyl carbon resonances of the p-cymene ligand were observed in the region around 17.1-294 
30.6 ppm whereas the aromatic carbon resonance were observed around 82.9-107.3 ppm. In 295 
addition to these carbon resonances the ring carbons of the Cp* ligand displayed signal around 296 
88.5-97.5 ppm whereas the methyl carbon resonances was observed as a sharp peak around 8.07-297 
8.89 ppm. Overall results from NMR spectral studies strongly support the formation of the metal 298 
complexes. 299 
Mass spectral studies of metal complexes 300 
The mass spectra of the complexes further confirmed the formation of the metal 301 
complexes. The mass spectra of all these complexes except complex (8) exhibited their 302 
predominant molecular ion peaks at m/z value which corresponds to [M-2H-2Cl+H]+ ion peak. 303 
For instance the mass spectrum of complex (6) displayed its molecular ion peak at m/z: 508.0924 304 
and the mass spectrum of complex (9) showed its molecular ion peak at m/z: 598.1507 (Figure 305 
S18 & S20). Both these peaks corresponds to [M-2H-2Cl+H]+ ion. In complex (8) peaks were 306 
observed at m/z: 542.0646 which is due to [M-2H-Cl]+ ion, and at m/z: 506.0881 which is due to 307 
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[M-2H-2Cl-1]+ ion (Figure S19). The mass ion peaks observed in these complexes are in 308 
accordance with similar reported complexes.[37] The mass spectral values strongly justify the 309 
composition and formulation of these complexes. 310 
Description of the crystal structures of complexes 311 
In addition to the spectroscopic analysis the coordination of the thiourea derived ligands 312 
to the metal ion was confirmed by carrying out the single crystal X-ray analysis. The detail 313 
regarding data collection and structure refinement parameters are summarized in (Table S1 & 314 
S2) and geometrical parameters including bond lengths, bond angles and metal atom involving 315 
ring centroid values are listed in (Table S3). The molecular structures of some of these 316 
complexes were established by carrying out the single crystal analysis which revealed the 317 
different coordination mode of the ligands to the metal and the geometry of the complexes. 318 
Crystal structures of complexes (4 and 7) contain two molecules in its asymmetric unit. X-ray 319 
analysis of these complexes featured a regular three legged piano-stool geometry with metal 320 
coordinated by π-bonded arene ring /Cp* ring (arene = p-cymene and Cp*) in a η6/η5 manner, 321 
nitrogen and sulfur donor atoms from thiourea derived ligands and terminal chloride. The 322 
geometry around the metal center can be regarded as pseudo-octahedral wherein the arene ligand 323 
forms the seat; thiourea derivatives and terminal chloride form the legs. The molecular structures 324 
of complexes (2 and 3) were established with PF6 counter ion. In cationic complexes (1-6) the 325 
preferable mode of coordination of the thiourea derived ligand to the metal is through the pyridyl 326 
and pyrimidyl nitrogen’s and thione sulfur probably due to increased stability of the metal sulfur 327 
bond as suggested by HSAB principle. 328 
Complexes (2 and 3) have the cationic species [Cp*M(L1)к2(N,S)Cl] {M = Rh and Ir} and 329 
counter anion PF6. In complexes (2 and 3) the metal center is coordinated through Cp* ring, 330 
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ligand (L1) in a bidentate fashion and terminal chloride thus possessing a three-legged piano-331 
stool structure. Ligand L1 acted as a neutral bidentate chelating ligand coordinating metal 332 
through pyrimidine nitrogen N(1) and thione sulfur S(1) thus forming a six membered 333 
metallacycle (Figure 1). 334 
Methyl substituted pyridyl thiourea derivatives coordinated metal in a different manner 335 
depending upon the position of the methyl group present at the pyridine ring. When methyl 336 
group is at the para position of the pyridine ring such as in benzoyl(4-picolyl)thiourea (L2) it 337 
acted as bidentate chelating ligand whereas when methyl group is at the ortho position of the 338 
pyridine ring as in benzoyl(6-picolyl)thiourea (L3) it behaved as neutral monodentate ligand. 339 
Previously we have shown that when methyl group is at the meta position of the pyridine ring 340 
such as in benzoyl(3-picolyl)thiourea it coordinated metal in a bidentate chelating manner.[17] 341 
Complexes (4, 5 and 6) also have the cationic species [(arene)M(L2)к2(N,S)Cl] [(arene) = p-342 
cymene, M = Ru and Cp*, M = Rh and Ir] and counter anion chloride. In these complexes the 343 
metal atom is coordinated through arene/Cp* ring (arene = p-cymene and Cp*) in a η6/η5 344 
manner, ligand L2 in a bidentate manner through pyridine nitrogen N(1) and thione sulfur atom 345 
S(1) forming a six membered chelate ring and terminal chloride thus featuring a three-legged 346 
piano-stool structure (Figure 2). 347 
In contrast complexes (7 and 8) have the neutral species having general formula 348 
[(arene)M(L3)к1(S)Cl2] [(arene) = p-cymene, M = Ru (7) and Cp*, M = Rh (8)]. In complexes (7 349 
and 8) the metal is coordinated through arene moiety, two chloride’s, and ligand L3 wherein it 350 
acted as a neutral monodentate ligand coordinating metal through thione sulfur (S1) (Figure 3). 351 
The probable reason for ligand L3 to act as monodentate ligand is due to the presence of methyl 352 
group at the ortho position of the pyridyl ring which is very close to pyridine nitrogen. 353 
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The distance between the metal (M) to centroid of the arene/Cp* ring are {1.795 (2), 354 
1.794 (3), 1.688 (4), 1.795 (5), 1.800 (6), 1.687 (7), 1.782 (8) and 1.801 (9) Å}. In cationic 355 
complexes (2-6) the metal to nitrogen bond distances were found to be in the range of 2.093-356 
2.131 Å while the metal to sulfur bond lengths was in the range of 2.321-2.412 Å. These bond 357 
lengths are consistent with the k2-N,S coordination of the thiourea derivatives which are found to 358 
be in close agreement with reported values.[32,33] The bite angle values in these cationic 359 
complexes were observed in the range of 84.7-91.3°. The metal to sulfur bond lengths in neutral 360 
complexes (7-9) is 2.410(2), 2.378(1) and 2.362(3) Å respectively. The M-S bond lengths in 361 
neutral complexes are slightly longer than that of cationic complexes (Table S3). The M-Cl bond 362 
lengths in these complexes shows no significant differences and was found to be in the range of 363 
2.399-2.438 Å which are comparable with earlier reported complexes.[17,18,34,35] The bond angle 364 
values S-M-Cl and Cl-M-Cl in neutral complexes (7-9) lay in the range of 87.7-95.5° (Table S3). 365 
The C-S bond length in these complexes lies in the range of 1.671-1.689 Å agrees well with 366 
those in other related compounds for a C=S double bond coordinated to a metal atom.[36-38] The 367 
C=O bond length lies in the range of 1.199-1.222 Å which purely indicates a double bond and 368 
which is not involved in coordination. The oxygen atom of carbonyl group is not involved in 369 
bonding to the metal also the deprotonation of amido hydrogen which was expected to alter the 370 
bonding modes of these ligands was also not observed as confirmed by 1H NMR and single 371 
crystal structures. Despite having a rich variety of bonding modes of these ligands it is 372 
interesting to note that these ligands preferably coordinated d6 metal (Ru, Rh and Ir) half-373 
sandwich complexes in a bidentate к2(N,S) and monodentate к1(S) manner. 374 
 375 
 376 
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Non-covalent interactions 377 
The crystal packing of these complexes showed the presence of several intermolecular 378 
and intramolecular hydrogen bonding. For instance in complex (5) the chloride counterion and 379 
H2O molecule interlinks the two asymmetric units through intermolecular hydrogen bonding. 380 
Also N-H∙∙∙Cl and C-H∙∙∙Cl intermolecular interactions are also observed (Figure 4). Complex 381 
(6) is stabilized by intermolecular N-H∙∙∙Cl, C-H∙∙∙Cl and O-H∙∙∙Cl interactions between the 382 
chloride counterion and hydrogen atoms from amido, H2O and aromatic ring. Also C-H∙∙∙O and 383 
C-H∙∙∙S interactions are observed and the chloride attached to iridium is involved in C-H∙∙∙Cl and 384 
O-H∙∙∙Cl intermolecular interactions (Figure 5). In complex (7) the two asymmetric units 385 
possessed intramolecular hydrogen bonding between the two chlorides attached to ruthenium and 386 
amido hydrogen. The pyridyl nitrogen is involved in N-H∙∙∙N interaction (Figure 6). Also the two 387 
asymmetric units are stabilized through a dimeric unit formed via intermolecular C-H∙∙∙Cl 388 
interaction between the two chlorides and aromatic hydrogen of p-cymene moiety (Figure 6). 389 
The non-covalent interactions present in these complexes provide an ideal platform for formation 390 
of complexes with interesting supramolecular features. 391 
Cytotoxicity studies against cancer cell line 392 
The cytotoxicity of the thiourea derivatives and its d6 metal complexes was evaluated by 393 
determining the IC50 values (the concentration of the drug required to inhibit the growth of 50 % 394 
of the cancer cells) against human colorectal (HCT-116 and HT-29) and pancreatic cancer (Mia-395 
PaCa-2) cells as well as against the non-cancerous human epithelial cell line (ARPE-19). 396 
Following a standard MTT protocol, cells were incubated with the compounds for 92 hours at 37 397 
°C over a range of different drug concentrations. The IC50 values of the compounds against HCT-398 
116, HT-29, Mi-PaCa-2 and ARPE-19 cells are presented in (Table 1). Because of the 399 
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hygroscopic nature of complexes (1 and 4) the cytotoxicity analysis could not be carried out. The 400 
thiourea ligands (L1-L3) were found to be inactive against both the cell lines with IC50 value > 401 
100 M (the highest drug concentration tested) whereas upon coordination of the ligands all the 402 
complexes possessed cytotoxicity. The enhanced cytotoxicity in complexes clearly indicates that 403 
the chelation of the thiourea derivatives with metal ion is responsible for the observed 404 
cytotoxicity. In the case of HCT-116 cells, complexes (2, 7 and 8) were found to possess 405 
moderate activity with IC50 value in the range of 11.42 ± 1.86 to 24.92 ± 1.91 µM, in contrast 406 
complexes (5, 6 and 9) were found to be more active exhibiting IC50 value in the low micromolar 407 
range of 5.18 ± 0.12 to 6.98 ± 0.50 M. Iridium complex (3) with ligand (L1) was found to be 408 
highly cytotoxic with IC50 value of 1.37 ± 0.09 M. This complex was found to be more active 409 
with low IC50 value of 1.37 ± 0.09 M as compared to cisplatin whose IC50 value is 2.78 ± 1.40 410 
M. In general the IC50 results shows the iridium compounds are more active as compared to 411 
ruthenium and rhodium. The higher cytotoxicity of the iridium compounds suggests that the 412 
presence of merely arene/Cp* ring or ligand is not only responsible for higher activity; the type 413 
of metal also plays a crucial role.  414 
Similar responses were observed with the other cancer cell lines with the exception of 415 
complex (3) where a broad range of potencies was observed (Table 1). This is also reflected in 416 
the selectivity indices where values ranging from 1.27 to 13.33 were observed (Table 2, Figure 417 
7). All the complexes showed less toxicity towards the normal cell line which is evident from its 418 
higher IC50 values. With regards to potency, statistically significant differences between the 419 
response of cancer cells line and ARPE-19 cells were observed for all the compounds. The 420 
cytotoxicity of these complexes was compared to that of other reported thiourea ruthenium 421 
complexes by Karvembu et.al.[34,37] Comparing these results, we found that our complexes 422 
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showed promising activity similar to related compounds. With regards to selectivity, all the 423 
complexes have selectivity for cancer cells. Complex (3) showed enhanced selectivity for HCT-424 
116 cells (13.33) as compared to cisplatin whose selectivity is (1.23). This suggests that complex 425 
(3) has more selectivity for cancer cells in vitro as compared to cisplatin. In addition, complex 426 
(3) has differential activity against different cancer cell lines suggesting that this complex is 427 
exploiting a specific target within this cell line. Further studies on structure–activity relationship 428 
will be carried out in future, which is expected to provide us a more insight into the specific 429 
activity of the complexes against various cancer cell lines. 430 
Table 1 IC50 values of thiourea ligands (L1-L3) and complexes along with cisplatin against 431 
HCT-116, HT-29, Mi-PaCa-2 cancer cell line and non-cancer cell line ARPE-19. Each value 432 
represents the mean ± standard deviation from three independent experiments. 433 
Compounds IC50 (µM) 
 HCT-116 Mia-PaCa-2 HT-29 ARPE-19 
L1 >100 >100 >100 >100 
L2 >100 >100 >100 >100 
L3 >100 >100 >100 >100 
Complex 1 Data not available Data not available Data not available Data not available 
Complex 2 24.92 ± 1.91 11.23 ± 0.49 23.27 ± 3.57 47.23 ± 0.63 
Complex 3 1.37 ± 0.09 14.33 ± 0.79 4.89 ± 0.56 18.26 ± 0.58 
Complex 4 Data not available Data not available Data not available Data not available 
Complex 5 6.98 ± 0.50 4.01 ± 0.12 4.9 ± 0.09 11.72 ± 0.30 
Complex 6 5.18 ± 0.12 4.48 ± 0.18 6.99 ± 0.51 9.79 ± 0.05 
Complex 7 11.42 ± 1.86 9.02 ± 0.13 13.47 ± 1.66 15.72 ± 0.83 
Complex 8 11.96 ± 2.19 6.21 ± 0.57 10.37 ± 0.17 16.24 ± 1.16 
Complex 9 5.50 ± 1.86 6.22 ± 0.07 8.09 ± 1.06 18.25 ± 0.48 
Cisplatin 2.78 ± 1.40 3.15 ± 0.09 2.58 ± 0.72 3.43 ± 0.48 
IC50 = concentration of the drug required to inhibit the growth of 50% of the cancer cells (µM). 434 
 435 
 436 
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Table 2 Selectivity indices of complexes and cisplatin in HCT-116, HT-29 and Mia-PaCa-2 437 
cancer cell lines. The selectivity index (SI) was calculated as the IC50 for ARPE-19 cells divided 438 
by the IC50 for either HCT-116 or MIA-PaCa-2 cells. 439 
Compounds Selectivity index 
(HCT-116) 
Selectivity index 
(Mia-PaCa-2) 
Selectivity index 
(HT-29) 
Complex 2 1.89 4.21 2.02 
Complex 3 13.33 1.27 3.73 
Complex 5 1.67 2.92 2.39 
Complex 6 1.89 2.18 1.40 
Complex 7 1.37 1.74 1.17 
Complex 8 1.36 2.62 1.56 
Complex 9 3.32 2.93 2.25 
Cisplatin 1.23 1.09 1.32 
Conclusion 440 
In this work, we report a series of cationic and neutral half-sandwich p-cymene 441 
ruthenium, Cp*rhodium and Cp*iridium complexes containing pyridyl and pyrimidyl thiourea 442 
derived ligands. Complexes containing ligands L1 and L2 were isolated as cationic complexes 443 
whereas complexes with ligand L3 was isolated as neutral complexes. The position of the methyl 444 
group in pyridyl thiourea ligands played a crucial role in determining whether the ligand would 445 
act as chelating or monodentate. X-ray crystallographic studies revealed that ligands L1 and L2 446 
acted as chelating bidentate ligand whereas L3 functioned as neutral monodentate ligand. In 447 
cationic complexes (2 and 3) ligand L1 coordinated metal through pyrimidyl nitrogen (N1) and 448 
sulfur atom S(1) whereas in complexes (4, 5 and 6) ligand L2 coordinated metal through pyridyl 449 
nitrogen N(1) and thione sulfur S(1). The coordination of the thione sulfur and nitrogen atoms to 450 
metal center allowed the formation of a six-membered chelate ring. In neutral complexes (7 and 451 
8) L3 acted as neutral monodentate ligand coordinating metal through thione sulfur (S1). The 452 
work presented here displays interesting coordination modes of the methyl substituted pyridyl 453 
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thiourea ligands depending upon the position of methyl substituent attached to the pyridine 454 
moiety. Pharmacologically, certain complexes are potent and selective activity against a panel of 455 
cancer cells was observed as compared to non-cancer cells. Whilst further studies are required to 456 
identify mechanisms of action, these compounds are promising leads for further development as 457 
potential anti-cancer agents. 458 
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